盐皮质激素受体拮抗剂与心房颤动:临床试验荟萃分析
结果显示MRAs在有/无心衰及有/无房颤患者中疗效一致,并可降低房颤事件风险(RR=0.76)。
要点
- MRAs可降低房颤事件风险(RR=0.76;95%CI 0.67-0.87)。
核心结论
- MRAs在有/无心衰患者中预防心血管事件疗效相似,且可能不受房颤状态影响。
- MRAs可能中度有效预防新发或复发房颤事件。
研究设计与样本
- 检索MEDLINE、Embase和Cochrane Central数据库至2023年3月24日,纳入评估MRAs对比安慰剂或常规治疗的随机对照试验。
- 采用随机效应模型和交互分析检验效应修饰。
主要发现
- MRAs降低房颤事件:RR=0.76(95%CI 0.67-0.87),在有/无既往房颤患者中均一致。
临床怎么用
- 对于有心衰或心血管风险的患者,MRAs的心血管获益不受心衰和房颤状态影响。
- MRAs可能用于预防新发或复发房颤事件,但需结合临床判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Mineralocorticoid receptor antagonists (MRAs) improve cardiovascular outcomes in a variety of settings. This study aimed to assess whether cardioprotective effects of MRAs are modified by heart failure (HF) and atrial fibrillation (AF) status and to study their impact on AF events. METHODS: MEDLINE, Embase, and Cochrane Central databases were searched to 24 March 2023 for randomized controlled trials evaluating the efficacy of MRAs as compared with placebo or usual care in reducing cardiovascular outcomes and AF events in patients with or at risk for cardiovascular diseases. Random-effects models and interaction analyses were used to test for effect modification. RESULTS: Meta-analysis of seven trials (20 741 participants, mean age: 65.6 years, 32% women) showed that the efficacy of MRAs, as compared with placebo, in reducing a composite of cardiovascular death or HF hospitalization remains consistent across patients with HF [risk ratio = 0.81; 95% confidence interval (CI): 0.67-0.98] and without HF (risk ratio = 0.84; 95% CI: 0.75-0.93; interaction P = .77). Among patients with HF, MRAs reduced cardiovascular death or HF hospitalization in patients with AF (hazard ratio = 0.95; 95% CI: 0.54-1.66) to a similar extent as in those without AF (hazard ratio = 0.82; 95% CI: 0.63-1.07; interaction P = .65). Pooled data from 20 trials (21 791 participants, mean age: 65.2 years, 31.3% women) showed that MRAs reduce AF events (risk ratio = 0.76; 95% CI: 0.67-0.87) in both patients with and without prior AF. CONCLUSIONS: Mineralocorticoid receptor antagonists are similarly effective in preventing cardiovascular events in patients with and without HF and most likely retain their efficacy regardless of AF status. Mineralocorticoid receptor antagonists may also be moderately effective in preventing incident or recurrent AF events.
引用
- Oraii A, Healey JS, Kowalik K, et al. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials. Eur Heart J. 2024. PMID: 38195054. doi:10.1093/eurheartj/ehad811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。